

**HOUSE . . . . . No.**

---

**The Commonwealth of Massachusetts**

PRESENTED BY:

**Gloria L. Fox**

*To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:*

The undersigned legislators and/or citizens respectfully petition for the passage of the accompanying bill:

**An Act promoting research and protecting public safety and environment.**

PETITION OF:

NAME:

Gloria L. Fox

DISTRICT/ADDRESS:

7th Suffolk

[SIMILAR MATTER FILED IN PREVIOUS SESSION  
SEE HOUSE, NO. 2097 OF 2007-2008.]

## The Commonwealth of Massachusetts

—————  
In the Year Two Thousand and Nine  
—————

### AN ACT PROMOTING RESEARCH AND PROTECTING PUBLIC SAFETY AND ENVIRONMENT..

*Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:*

1 SECTION 1. Chapter 17 of the General Laws, as appearing in the 2004 official edition is hereby amended by  
2 inserting after section 17 the following:-  
3

4 Section 18. Biological Agents Registry Program

5

6 (a) Definitions. As used in this section the following words shall have the following meanings:  
7

8 “Biological agent,” any microorganism (including bacteria, virus, fungus, and protozoa), or infectious substance, or  
9 any naturally occurring, bioengineered, or synthesized component of any such microorganism or infectious  
10 substance, capable of causing: death, disease, or other biological malfunction in a human, an animal, a plant, or  
11 another living organism; deterioration of food, water, equipment, supplies, or material of any kind; or deleterious  
12 alteration of the environment.

13

14 “Department,” the Department of Public Health.

15

16 “Person,” any state, public, or private corporation or authority, any individual, trust, firm, joint stock company,  
17 partnership, association, or other entity, or any group thereof, and any officer, employee, or agent of such person,  
18 any group of persons, and any agency or political subdivision of the Commonwealth or of the federal government.

19

20 “Program,” the Biological Agents Registry Program.

21

22 “Select Agents and Toxins” a biological agent or toxin as defined in Title 42, Part 73 of the Code of Federal  
23 Regulations, Title 9, Part 121 of the Code of Federal Regulations, or Title 7, Part 331 of the Code of Federal  
24 Regulations.  
25

26 “Toxin,” any toxic material or product of plants, animals, microorganisms (including bacteria, virus, fungus,  
27 rickettsiae, or protozoa), or infectious substance, or a recombinant or synthesized molecule, whatever their origin  
28 and method of production, and includes: any poisonous substance or biological product that may be engineered as a  
29 result of biotechnology produced by a living organism; or any poisonous isomer or biological product, homolog, or  
30 derivative of such a substance.

31  
32 (b) There is established in the department a Biological Agents Registry Program.

33  
34 (c) The Biological Agents Registry shall:

35  
36 (1) Identify the select agents and toxins, and other biological agents and toxins, as determined by the  
37 department, possessed and maintained by any person in the Commonwealth; and

38  
39 (2) Contain other information as required by regulations of the department.

40  
41 (d) The department shall adopt regulations for the implementation of the program that:

42  
43 (1) Determine and list the biological agents and toxins required to be reported under this section, which shall  
44 include:

45  
46 i. All select agents and toxins, provided that the department may exempt select agents and toxins  
47 that Title 42, Part 72 or 73 of the Code of Federal Regulations, Title 9, Part 121 of the Code of  
48 Federal Regulation, or Title 7, Part 331 of the Code of Federal Regulations exempt from their  
49 provisions; and

50 ii. Other biological agents and toxins as determined by the department.

51  
52 (2) Designate the persons required to make reports and the specific information required to be reported;

53  
54 (3) Designate time limits for reporting, the form of reports, and the persons to whom reports are to be  
55 submitted;

56  
57 (4) Require local boards of health to be informed of the location and nature of the biological agents and toxins  
58 in the registry that are located within the local jurisdiction;

59  
60 (5) Provide for the release of information in the Biological Agents Registry to:

61  
62 i. Municipal, state and federal law enforcement agencies and the Centers for Disease Control and  
63 Prevention pursuant to a communicable disease or laboratory-acquired infection investigation  
64 commenced or conducted by the department or municipal, state, or federal law enforcement agency  
65 having investigatory authority, or in connection with any investigation involving a release, spread,  
66 theft, illicit sale, or loss of biological agents;

67  
68 ii. The Massachusetts emergency management agency and the Massachusetts department of the  
69 environmental protection for the purposes of planning for the protection of the public in relation to  
70 the release of a biological agent and the prevention of a release of a biological agent; and

71  
72 iii. The Massachusetts emergency medical services system for the purposes of providing certain  
73 specified information to:

74  
75 (A) A police officer or firefighter responding to an emergency; and

76  
77 (B) An emergency medical services provider performing emergency services responding to a  
78 fire or other emergency, or dispatched on a call for emergency services;

79

80 (6) Establish a process for persons that possess and maintain select agents and toxins and other biological  
81 agents and toxins to alert appropriate authorities of unauthorized possession or attempted possession of  
82 such biological agents or toxins.  
83

84 (e) A person that possesses and maintains biological agents and toxins shall report to the department the  
85 information required by the department for inclusion in the Biological Agents Registry unless the department  
86 determines that the select agents and toxins, certified laboratory, or facility is exempt from the requirements for  
87 the interstate shipment of etiologic agents under Title 42, Part 72.6(h) or Part 72, Appendix A of the Code of  
88 Federal Regulations.  
89

90 (f) Information prepared for or maintained in the Biological Agents Registry shall be subject to chapter 66 of the  
91 General Laws, provided that information released from the Registry is not consequently a public record and a  
92 person to whom information has been released from the Registry may not release the information unless such  
93 release is approved by the department.  
94

95 (g) A person who violates a provision of this section is guilty of a misdemeanor and on conviction is subject to a  
96 fine not exceeding \$1000 for the first offense and not exceeding \$5000 for each subsequent conviction for a  
97 violation of the same provision. Each day a violation is continued after the first conviction is a subsequent  
98 offense.  
99

#### 100 Section 19. High Containment Biological Research Laboratory Health and Safety Program

101 (a) Definitions. As used in this section the following words shall have the following meanings:

102  
103  
104  
105 “Biological agent,” any microorganism (including bacteria, virus, fungus, and protozoa), or infectious substance, or  
106 any naturally occurring, bioengineered, or synthesized component of any such microorganism or infectious  
107 substance, capable of causing: death, disease, or other biological malfunction in a human, an animal, a plant, or  
108 another living organism; deterioration of food, water, equipment, supplies, or material of any kind; or deleterious  
109 alteration of the environment.  
110

111 “Biosafety in Microbiological and Biomedical Laboratories” or “BMBL,” a publication that lists the standards and  
112 special microbiological practices, safety equipment and facilities constituting Biosafety Levels 1-4, most recent  
113 edition, published by the United States Department of Health and Human Services, Public Health Service, the  
114 Centers for Disease Control and Prevention and the National Institutes of Health. If the publication is discontinued,  
115 the most recent edition shall remain in effect as thereafter modified from time to time by regulation of the  
116 department.  
117

118 “Biosafety Level 3 laboratory” or “BSL3 laboratory,” a laboratory that is designed, equipped, or operated as a  
119 biosafety level 3 laboratory as defined by the United States National Institutes of Health Guidelines for Research  
120 Involving Recombinant DNA Molecules (NIH Guidelines).  
121

122 “Biosafety Level 4 laboratory” or “BSL4 laboratory,” a laboratory that is designed, equipped, or operated as a  
123 biosafety level 4 laboratory as defined by the United States National Institutes of Health Guidelines for Research  
124 Involving Recombinant DNA Molecules (NIH Guidelines).  
125

126 “Department,” the Department of Public Health.  
127

128 “Facility,” a building or combination of buildings under common control and ownership containing one or more  
129 laboratories subject to a common Institutional Biosafety Committee.  
130

131 “High Containment Biological Research Laboratory,” a BSL3 or BSL4 laboratory.  
132

133 “Laboratory,” a room or rooms that are used primarily for biological research, development, non-routine testing, or  
134 experimentation activity, or any room or rooms where vertebrate animals are contained under animal biosafety

135 levels three and four as described in NIH Guidelines/BMBL Section IV. The word “laboratory” shall also include  
136 those rooms that directly serve a laboratory and are within the containment area.  
137

138 “National Institutes of Health Guidelines” or “NIH Guidelines,” the National Institutes of Health Guidelines for  
139 Research Involving Recombinant Molecules, as amended from time to time. If the National Institutes of Health  
140 shall discontinue or abolish said guidelines, the most recent guidelines shall remain in effect as thereafter modified  
141 from time to time by regulation by the department.  
142

143 “Person,” any state, public, or private corporation or authority, any individual, trust, firm, joint stock company,  
144 partnership, association, or other entity, or any group thereof, and any officer, employee, or agent of such person,  
145 any group of persons, and any agency or political subdivision of the Commonwealth or of the federal government.  
146

147 “Program,” the High Containment Biological Research Laboratory Health and Safety Program.  
148

149 “Select Agents and Toxins,” a biological agent or toxin as defined in Title 42, Part 73 of the Code of Federal  
150 Regulations, Title 9, Part 121 of the Code of Federal Regulations, or Title 7, Part 331 of the Code of Federal  
151 Regulations.  
152

153 “Toxin,” any toxic material or product of plants, animals, microorganisms (including bacteria, virus, fungus,  
154 rickettsiae, or protozoa), or infectious substance, or a recombinant or synthesized molecule, whatever their origin  
155 and method of production, and includes: any poisonous substance or biological product that may be engineered as a  
156 result of biotechnology produced by a living organism; or any poisonous isomer or biological product, homolog, or  
157 derivative of such a substance.  
158

159 (b) There is established in the department a High Containment Biological Research Laboratory Health and Safety  
160 Program.  
161

162 (c) The program shall provide standards for the location, operation, and maintenance of high containment  
163 biological research laboratories and the oversight of such laboratories to protect the safety of laboratory  
164 workers, the public, and the environment from select agents and toxins.  
165

166 (d) The department shall adopt regulations for the implementation of the program that:  
167

168 (1) Set criteria for determining appropriate locations for siting a building with a BSL4 laboratory, including  
169 whether a BSL4 laboratory may be created within an existing building, that at a minimum include that:  
170

171 i. Sites shall not be within a floodplain, near a property whose regular use could significantly  
172 endanger the site through fire or explosion, or near an area of high traffic congestion that might  
173 impede emergency access or evacuation or endanger motorists;  
174

175 ii. Sites shall have sufficient land available to provide for a reasonable buffer around the building, a  
176 minimum of 150 unobstructed feet in every direction;  
177

178 iii. Other criteria for consideration include: the proximity of flood plains, wetlands, waterways, and  
179 water bodies; the relationship of the site to groundwater elevations; the nature and extent of  
180 residential areas and schools through grade twelve in proximity to the site; the availability and  
181 suitability of access roads to the site, including the ability of first responders to access the site in an  
182 emergency; the potential for adverse public health and safety impacts; the potential impact of  
183 increased traffic volume on roads to the site; and the potential threat of a terrorist attack on or  
184 infiltration of the building.  
185

186 (2) Provide a process to determine whether to approve the siting of a new BSL4 laboratory that includes:  
187

188 i. An application to be completed by a person wishing to site a building with a BSL4 laboratory or  
189 add a BSL4 laboratory to an existing building that did not have a BSL4 laboratory;  
190

191 ii. The department holding a public hearing on the application in the municipality where the  
192 laboratory would be located;  
193  
194 iii. The department, the department of environmental protection, the board of health of the  
195 municipality in which the facility would be located reviewing the application and approving the  
196 siting if they determine that the proposed site and building would not constitute a threat to the public  
197 health or safety or the environment;  
198  
199 iv. The decision on the siting is made in writing with findings as to why the decision was made;  
200  
201 v. The approval or denial of siting may be appealed pursuant to provisions of section fourteen of  
202 chapter thirty A;  
203  
204 (3) Require each facility with a BSL4 laboratory that has been approved as required by subsection (2) to  
205 submit to the department the construction plans for the facility, construction schedule, the application  
206 submitted to the National Institutes of Health (NIH), if applicable, the as-built plans when completed, and  
207 documentation of third-party commissioning of the facility.  
208  
209 (4) Assure that high containment biological research laboratories meet or exceed federal guidelines for health  
210 and safety practices, including that:  
211  
212 i. Each facility with a high containment biological research laboratory complies with the most  
213 current versions of the following guidelines: NIH Guidelines; BMBL; and Guidelines on Primary  
214 Containment for Biohazards (Centers for Disease Control/NIH); or more protective regulations that  
215 the department might adopt.  
216  
217 ii. Each facility with a high containment biological research laboratory shall establish an  
218 Institutional Biosafety Committee (IBC) in accordance with the NIH Guidelines, whether it is NIH  
219 funded or not. At least two members of the IBC shall be residents of the municipality in which the  
220 facility is located and shall be independent of the facility, its contractors, and consultants. One such  
221 member shall be appointed by the department and the other shall be appointed by the local board of  
222 health. A member appointed by the department or local board of health may be rejected by the  
223 facility only for good cause.  
224  
225 iii. An IBC shall comply with NIH Guidelines applicable to IBCs for all research in high containment  
226 biological research laboratories, whether recombinant DNA research or not, and may be further  
227 regulated by the department. Each IBC for a facility with high containment biological research  
228 laboratory shall, at a minimum:  
229  
230 (A) Provide the department with a complete list of all members of the IBC, including member's  
231 name, title, business mailing address, phone number, fax number, e-mail, and curriculum vitae.  
232 The list and curriculum vitae shall be updated with any changes at least annually.  
233  
234 (B) Review and approve all projects in facilities operating a high containment biological  
235 research laboratory prior to the projects commencing. A protocol registration document, as  
236 defined by the NIH guidelines, shall be required for all approved IBC projects with select agents  
237 and toxins and other regulated agents requiring BSL3 or BSL4 containment. The documents  
238 shall be sent to the department and are subject to chapter 66 of the General Laws.  
239  
240 (C) Take and keep minutes of IBC meetings that conform to the NIH Guidelines and provide the  
241 minutes to the department. The minutes shall be accessible for members who do not attend the  
242 meetings. The minutes shall include, but not be limited to: IBC members present at the  
243 meeting; a description of any current or pending research; any comments or concerns made at  
244 the meeting; and any voting, administrative matters, accident reporting or compliance issues  
245 discussed. The department may provide the minutes to the local board of health upon request.  
246

247 (D) Inspect the high containment biological research laboratories at least annually and submit  
248 the results of the inspections to the department.

249  
250 (E) Meet at least annually with a representative of the department to review safety procedures,  
251 discuss health issues relating to operation of its facility, and such other issues identified by the  
252 department.

253  
254 (F) Hold at least one public meeting annually to a report on health and safety issues at the  
255 facility and take public comments about the facility.

256  
257 (5) Require prior approval by the department for research that may or is intended to:

258  
259 i. Enhance the harmful consequences of a biological agent or toxin. Harmful consequences include  
260 the ability to critically alter normal biological functions, or inflict damage on public health resources,  
261 materiel, and public safety. Enhancement includes augmenting properties such as virulence,  
262 infectivity, stability, transmissibility, or the ability of the biological agent or toxin to be  
263 disseminated;

264  
265 ii. Disrupt immunity or the effectiveness of an immunization;

266  
267 iii. Confer to a pathogenic agent or toxin resistance to clinically or agriculturally useful prophylaxes  
268 or therapeutics against that agent or toxin;

269  
270 iv. Facilitate the ability of a biological agent or toxin to evade detection methodologies;

271  
272 v. Increase the stability, transmissibility, or the ability to disseminate a biological agent or toxin;

273  
274 vi. Alter the host range or tropism of a pathogenic agent or toxin;

275  
276 vii. Enhance the susceptibility of a host population, including by immuno-modulation of the host to  
277 increase pathogenicity; or

278  
279 viii. Generate a novel pathogenic agent or toxin or reconstitute an eradicated or extinct pathogenic  
280 agent. A novel agent is an agent that has not existed previously and is considered unique based on  
281 biological or other properties and traits.

282  
283 Such approval may be granted only upon a showing that the facility has taken special precautions to  
284 minimize or eliminate health and safety risks arising from such research.

285  
286 (6) Require each facility with a high containment biological research laboratory to complete a permit  
287 application and obtain a permit from the department to operate its high containment biological research  
288 laboratories. Said permits shall contain the terms and conditions the department determines are necessary  
289 to protect worker and public health and safety and the environment. Said permits shall not exceed five  
290 years in duration but may be renewed or reissued by the department after receipt of a new completed  
291 permit application that meets regulatory requirements. The department may issue or renew a permit only  
292 upon finding that no condition or circumstance exists in the facility that is prejudicial to worker or public  
293 health and safety or the environment. The department may suspend or revoke a permit upon finding that a  
294 condition or circumstance exists in the facility that is prejudicial to worker or public health and safety or  
295 the environment.

296  
297 (7) Require each facility with a high containment biological research laboratory to have a medical  
298 surveillance plan created in consultation with a licensed physician experienced in occupational health or  
299 infection control and familiar with biological laboratory exposures and informed about select agents and  
300 toxins. The purpose of the plan is to establish employee and researcher occupational health records,  
301 document and require inoculation for diseases when a safe vaccine is available, screen for illness among  
302 laboratory workers, require reporting of laboratory accidents, monitor and track releases and laboratory-

303 acquired infections and spreads, and report within the facility and to appropriate government entities. The  
304 specifics of the medical surveillance and infection control protocol must meet standards established by the  
305 department and be approved by the department. The medical surveillance plan shall be implemented  
306 through an employee experienced in occupational health or infection control, familiar with biological  
307 laboratory exposures, and informed about select agents and toxins. The employee shall also:

- 308
- 309 i. Report any accidental or intentional human exposure to a pathogenic biological agent or toxin, or  
310 reasonable likelihood of such exposure, to the department as soon as possible and in no case more  
311 than 24 hours after learning of the exposure;  
312
- 313 ii. Report any accidental or intentional release or spread of a pathogenic biological agent or toxin, or  
314 reasonable likelihood of a release or spread, outside the containment area of a BSL 3 or BSL4  
315 laboratory to the department as soon as possible, and in no case more than 24 hours after the release.  
316 The report also shall be provided to the board of health in the municipality in which the facility is  
317 located and any other municipality affected by the release.  
318
- 319 iii. Provide the IBC with a report of all incidents, accidents, and other events that caused or are  
320 suspected to have caused a threat to the public health, death, illness, or bodily injury to any person in  
321 the laboratory, as they occur, but no later than 3 days after the incident.  
322
- 323 (8) Require each facility with a high containment biological research laboratory to have and implement a  
324 plan to provide adequate training for the proper handling of pathogenic biological agents and toxins that  
325 might be present in the laboratory. Such training shall include, but not be limited to, decontamination  
326 methods, personnel safety precautions and work habits, early warning disease surveillance, and accident  
327 response actions and notifications. The facility shall provide a training plan to its IBC and the department  
328 for approval and shall update the plan annually, if necessary. The training plan shall ensure that all  
329 laboratory staff and researchers, including the principal investigator for each facility, are trained  
330 adequately and that the principal investigator participates in the creation and implementation of the  
331 training plan. No individual other than a local, state or federal government representative requiring access  
332 for regulatory compliance or investigative purposes may enter a high containment biological research  
333 laboratory located within a facility without first completing the facility's training plan.  
334
- 335 (9) Require each facility with a high containment biological research laboratory to have and implement a  
336 waste management and decontamination plan approved by the department.  
337
- 338 (e) A facility with a high containment biological research laboratory shall develop an emergency response plan, in  
339 conjunction with local and state officials, that addresses security threats and releases and spread of pathogenic  
340 biological agents and toxins. The emergency response plan shall comply with local, state or federal plans  
341 already in existence. The plan must address such events as severe weather (such as hurricanes and floods),  
342 earthquakes, power outages, terrorism, and other natural, accidental, or intended disasters or emergencies. The  
343 emergency response plan shall at a minimum address the following:  
344
- 345 (1) The hazards associated with the use of the select agents and toxins and special procedures needed to  
346 address the hazards of specific select agents and toxins.  
347
- 348 (2) Personnel roles, lines of authority, training, and communication.  
349
- 350 (3) Emergency assessment and prevention.  
351
- 352 (4) Site security and control.  
353
- 354 (5) Evacuation routes and procedures.  
355
- 356 (6) Decontamination.  
357
- 358 (7) Emergency medical treatment and first aid.



- 359  
360 (8) Emergency alerting and response procedures.  
361  
362 (9) Personal protective and emergency equipment.  
363  
364 (10) Regularly scheduled preparedness exercises in coordination with local public health and safety officials.  
365  
366 (11) Critique of response and follow-up after an incident has occurred.  
367  
368 (12) Communication to the public and news media.  
369
- 370 (f) A facility with a BSL4 laboratory shall coordinate with a hospital within a five mile radius of the facility for a  
371 medical response to human exposure to a pathogenic biological agent or toxin, and do so in conformity with  
372 existing public health guidelines and regulations. If there is no hospital medically equipped to coordinate this  
373 type of response within a five mile radius of said facility, then the coordination shall be performed at the closest  
374 hospital to the facility so equipped. Said coordination shall include, but not be limited to, addressing  
375 transportation, isolation, and quarantine issues as appropriate to the diseases caused by select agents and toxins  
376 at the facility. If the closest hospital has created a plan in collaboration with the department under the  
377 Bioterrorism Grant Program, the facility is not required to pay for the cost of annual drills.  
378
- 379 (g) Every facility that has a high containment biological laboratory shall purchase property and general liability  
380 insurance. The insurance shall provide compensation for harm that would be caused to facility workers and the  
381 public in the event of a release of a toxin or agent or other hazardous exposure to dangerous pathogens, and  
382 from damages caused by a terrorist attack on the facility.  
383
- 384 (h) No employee, researcher, or student shall be required to conduct scientific research, experimentation, or study  
385 or take other action in a facility with a high containment biological research laboratory that violates any  
386 provision of this section or has reasonable potential to adversely affect public or worker health, safety, or the  
387 environment.  
388
- 389 (i) A facility with a high containment biological research laboratory shall not take any retaliatory action against an  
390 employee, researcher, or student in the facility because that person discloses or threatens to disclose to a  
391 supervisor or a public body an activity, policy or practice that the employee, researcher or student reasonably  
392 believes is in violation of this section or objects to or refuses to participate in any activity, policy or practice that  
393 the employee, researcher or student reasonably believes is in violation of this section.  
394
- 395 (1) The protection against retaliatory action shall not apply to the public disclosure of confidential or  
396 proprietary information, trade secrets or other confidential materials unless the employee, researcher or student  
397 makes such disclosure directly and exclusively to the office of the attorney general or the department. The  
398 department shall not publicly disclose any such confidential information, but shall submit the information to the  
399 Attorney General forthwith.  
400
- 401 (2) An employee, researcher or student aggrieved by a violation of this subsection may, within two years, file  
402 a complaint with the attorney general, who may bring an action in the name of the Commonwealth against the  
403 facility alleged to have violated this section. Provided further, that within ninety days of receiving said  
404 complaint, the attorney general shall notify the complainant in writing as to whether he intends to bring an  
405 action in the name of the Commonwealth. If the attorney general declines to bring an action based on the  
406 complaint filed, the aggrieved employee, researcher or student may, within one year, institute a civil action in  
407 the superior court. Any party to said action shall be entitled to claim a jury trial. All remedies available in  
408 common law tort actions shall be available to prevailing plaintiffs. These remedies are in addition to any legal  
409 or equitable relief provided herein. The court may: (i) issue temporary restraining orders or preliminary or  
410 permanent injunctions to restrain continued violation of this section; (ii) reinstate the employee, researcher or  
411 student to the same position held before the retaliatory action, or to an equivalent position; (iii) reinstate full  
412 fringe benefits and seniority rights to the employee, researcher or student; (iv) compensate the employee,  
413 researcher or student for three times the lost wages, benefits and other remuneration, and interest thereon; and  
414 (v) order payment by the facility of reasonable costs, and attorneys' fees.

415  
416 (3) In any action brought by an employee, researcher or student under subsection (2), if the court finds said  
417 action was without basis in law or in fact, the court may award reasonable attorneys' fees and court costs to the  
418 facility. An employee, researcher or student shall not be assessed attorneys' fees if, after exercising reasonable  
419 and diligent efforts after filing a suit, the employee, researcher or student moves to dismiss the action against  
420 the facility, or files a notice agreeing to a voluntary dismissal, within a reasonable time after determining that  
421 the facility would not be found liable for damages.  
422

423 (4) Nothing in this subsection shall be deemed to diminish the rights, privileges or remedies of any employee,  
424 researcher or student under any other federal or state law or regulation, or under any collective bargaining  
425 agreement or employment contract.  
426

427 (5) A facility with a high containment biological research laboratory shall publicly display notices designed to  
428 inform its employees, researchers and students of their protections and obligations under this subsection, and  
429 use other appropriate means to keep its employees, researchers or students so informed. Each notice posted  
430 pursuant to this subsection shall include the name of the person or persons the facility has designated to receive  
431 written notification of a suspected violation of this section.  
432

433 (j) A facility with a high containment biological research laboratory shall have a security plan developed in  
434 coordination with state and local public safety officials. The security plan shall describe the deployment of  
435 security guards; the number of guards at each facility; other protective measures, including, coordination of  
436 security response with Federal, State, and Local authorities; restricted personnel access to each BSL3 and BSL4  
437 laboratory; perimeter site security, internal site security, and fire protection barriers; and background security  
438 clearance for employees and prospective employees. If, at any time, the department of public safety determines  
439 that the security plan or implementation of the security plan for a BSL3 or BSL4 facility or laboratory is  
440 insufficient to ensure its security, the municipality or department of public safety shall submit to the facility a  
441 report that identifies the vulnerability of the facility or laboratory, and recommended actions to eliminate the  
442 vulnerability. Said recommendations or other remedial actions shall be implemented by the facility  
443 immediately.  
444

445 (k) To ensure compliance with this section and to protect the public health and safety and the environment, the  
446 department shall have the authority to review all documentation relating to the operations of a high containment  
447 biological research laboratory and conduct physical inspections of any such laboratory, and any other part of a  
448 facility that supports the laboratory, with or without prior notice; so long as such inspections are conducted at  
449 reasonable times and in a manner that maintains the health and safety systems of the laboratory.  
450

451 (l) A person who willfully or knowingly violates this section or a regulation promulgated pursuant to this section  
452 is subject to judicially imposed criminal and civil penalties as well as civil administrative penalties. Each day  
453 that a violation occurs or continues constitutes a separate violation. A violation may be punished by the  
454 administrative imposition of a penalty of not less than \$100 and not more than \$25,000 for each day of  
455 violation. A violation may be punished by a fine not less than \$100 and not more than \$25,000, or by  
456 imprisonment for not more than two years in the house of correction. Punishment imposed under this section  
457 does not preclude any other penalty prescribed by law.  
458

459 (m) If a facility or laboratory remains in violation of this section or a regulation promulgated pursuant to this  
460 section after written notice from the department without taking reasonable steps to alleviate the violation, the  
461 department shall have the authority to close the facility or laboratory until the violation is remedied. If the  
462 department finds that an imminent and substantial threat to worker or public health or safety or the environment  
463 exists in a facility or laboratory, it may request the attorney general bring suit or an action for injunctive relief.  
464

465 (n) Each municipality in the Commonwealth shall have the authority to regulate and prohibit high containment  
466 biological research laboratories within its jurisdiction. If a municipality has a regulatory program for high  
467 containment biological research laboratories that the department finds is at least as protective of worker and  
468 public health and safety and environment as this program, upon request of the municipality the department may  
469 certify the municipal program to operate in the place of this program in the municipality.  
470

471

472 SECTION 2. The Department of Public Health shall adopt regulations to implement this act within one year after  
473 the effective date of this act.

474

475 SECTION 3. Section 19(d)(2), concerning whether to approve the siting of a new BSL4 laboratory, shall not apply  
476 to any building intended to include a BSL4 laboratory that has a building permit and is under construction as of the  
477 effective date of this act.